Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7476285 | 0.82 | GAA (0.40) | TRPV4ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL1462094 | 0.82 | TAS1R3 (0.36) | TRPV4ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL4323122 | 0.81 | TRPV4 (0.48) | TRPV4ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL7920588 | 0.79 | KIF11 (0.42) | TRPV4KDM4EALDH1A1HPGDGAA | |
| SCHEMBL3986261 | 0.78 | KDM4E (0.44) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL14783801 | 0.78 | KDM4E (0.44) | ADORA2AADORA1KDM4EALDH1A1HPGD | |
| SCHEMBL29906554 | 0.76 | TRPV4 (0.37) | TRPV4ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL2597730 | 0.76 | TRPV4 (0.37) | TRPV4ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL9899689 | 0.75 | TDP1 (0.42) | ALDH1A1HPGDMAPTCUL4ALMNA | |
| SCHEMBL186689 | 0.74 | TRPV4 (0.42) | TRPV4ADORA2AADORA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| EP-2493865-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010025451-A2 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056374-A1 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056374-A1 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056374-A1 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | US | disclosed |
| US-5883102-A | Pharmaceutically active compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 1999-03-16 | — | — | US | disclosed |
| CN-1204327-A | Pharmaceutically active quinazoline compounds | ASTRA PHARMA PROD (GB) | 1999-01-06 | — | — | CN | disclosed |
| EP-0858451-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997014686-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | TRPV4 3319/4885ADORA2A 2367/4885ADORA1 995/4885 |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | TRPV4 3319/4885ADORA2A 2367/4885ADORA1 995/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | TRPV4 3319/4885ADORA2A 2367/4885ADORA1 995/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | TRPV4 3319/4885ADORA2A 2367/4885ADORA1 995/4885 |
| US-20100056374-A1 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | NQO2, DDT, RAB7A | TRPV4 3237/4885ADORA2A 2495/4885ADORA1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.